AstraZeneca’s Enhertu received a positive EU recommendation for residual HER2-positive early breast cancer, after DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence or death versus T-DM1. For investors, the opinion advances Enhertu toward a potential new early-breast-cancer standard in the EU if approved.
Key Highlights
- Enhertu was recommended for EU approval as adjuvant monotherapy for adults with resected HER2-positive breast cancer and residual invasive disease after neoadjuvant treatment.
- DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence or death versus T-DM1.
- DESTINY-Breast05 showed a 53% reduction in invasive disease recurrence or death with Enhertu versus T-DM1.
ASTRAZENECA PLC (NYSE: AZN) is a major pharmaceuticals company. Enhertu has received a positive recommendation in the European Union for adults with residual invasive HER2-positive early breast cancer after neoadjuvant treatment, with DESTINY-Breast05 showing a 53% reduction in invasive disease recurrence or death versus T-DM1. The recommendation is for adjuvant treatment.
EU Recommendation Covers Residual Disease
The opinion drew on the global, randomised, open-label DESTINY-Breast05 Phase III trial. The trial’s primary measure was investigator-assessed invasive disease-free survival.
Trial Results Support Potential Standard of Care
DESTINY-Breast05 produced a hazard ratio of 0.47, with a 95% confidence interval of 0.34-0.66 and p<0.0001. T-DM1 is the current standard of care in the EU for this adjuvant setting among patients with residual invasive disease. Enhertu and T-DM1 were evaluated in patients at high risk of recurrence following neoadjuvant therapy.
FAQs
Q: What did the EU recommend for AstraZeneca’s Enhertu?
A: The EU recommendation covers Enhertu as a monotherapy for adults with resected HER2-positive breast cancer and residual invasive disease after neoadjuvant treatment.
Q: How many patients were enrolled in the DESTINY-Breast05 trial?
A: The article does not state how many patients were enrolled in DESTINY-Breast05. It describes the study as a global, randomised, open-label Phase III trial.
Q: Who developed Enhertu?
A: Daiichi Sankyo discovered Enhertu, while AstraZeneca and Daiichi Sankyo jointly develop and commercialise the medicine. Daiichi Sankyo is responsible for manufacturing and supply.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.